WallStreetZenWallStreetZen

NASDAQ: FLGC
Flora Growth Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their FLGC stock forecasts and price targets.

Forecast return on equity

Is FLGC forecast to generate an efficient return?

Company
-15.1%
Industry
22.8%
Market
-17.91%
FLGC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is FLGC forecast to generate an efficient return on assets?

Company
-2.68%
Industry
11.77%
FLGC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FLGC earnings per share forecast

What is FLGC's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$23.05
Avg 2 year Forecast
-$1.05

FLGC revenue forecast

What is FLGC's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$50.7M-3.27%
Avg 2 year Forecast
$56.0M+6.87%
FLGC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

FLGC revenue growth forecast

How is FLGC forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-3.27%
Industry
3.01%
Market
118.05%
FLGC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
FLGC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

FLGC vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
FLGC$24.30N/AN/A
AYTU$2.21$10.00+352.49%Strong Buy
TXMD$1.17N/AN/A
GELS$1.33N/AN/A
IXHL$0.38N/AN/A
View Top Pharmaceutical Stocks

Flora Growth Stock Forecast FAQ

What is FLGC's earnings growth forecast for 2025-2026?

(NASDAQ: FLGC) Flora Growth's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 216.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 54.97%.

Flora Growth's earnings in 2025 is -$13,073,000.On average, 1 Wall Street analyst forecast FLGC's earnings for 2025 to be -$13,336,849, with the lowest FLGC earnings forecast at -$13,336,849, and the highest FLGC earnings forecast at -$13,336,849.

In 2026, FLGC is forecast to generate -$607,617 in earnings, with the lowest earnings forecast at -$607,617 and the highest earnings forecast at -$607,617.

If you're new to stock investing, here's how to buy Flora Growth stock.

What is FLGC's revenue growth forecast for 2025-2026?

(NASDAQ: FLGC) Flora Growth's forecast annual revenue growth rate of -3.27% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 118.05%.

Flora Growth's revenue in 2025 is $52,373,000.On average, 1 Wall Street analysts forecast FLGC's revenue for 2025 to be $29,316,081, with the lowest FLGC revenue forecast at $29,316,081, and the highest FLGC revenue forecast at $29,316,081.

In 2026, FLGC is forecast to generate $32,388,888 in revenue, with the lowest revenue forecast at $32,388,888 and the highest revenue forecast at $32,388,888.

What is FLGC's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: FLGC) forecast ROA is -2.68%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 11.77%.

What is FLGC's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: FLGC) Flora Growth's current Earnings Per Share (EPS) is -$34.32. On average, analysts forecast that FLGC's EPS will be -$23.05 for 2025, with the lowest EPS forecast at -$23.05, and the highest EPS forecast at -$23.05. In 2026, FLGC's EPS is forecast to hit -$1.05 (min: -$1.05, max: -$1.05).

What is FLGC's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: FLGC) forecast ROE is -15.1%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.